Trytosaveabit OP : Investor Highlights:
Strategic Expansion:
This partnership highlights SINTX's expansion into the high-growth field of radio therapeutics, a market projected to see substantial growth over the coming years.
Innovative Technology:
The use of SINTX's proprietary ceramic microsphere technology is expected to optimize dosing and enhance treatment precision to improve patient outcomes, positioning SINTX as a front-runner in the field of targeted radio-therapeutic devices.
Robust Pipeline:
The agreement paves the way for potential future collaborations, including scaling production, further testing to meet regulatory requirements, and expanded indications within the oncology and musculoskeletal spaces.
Through this collaboration, SINTX aims to unlock new revenue opportunities and strengthen its position in the medical device sector, making it an attractive prospect for current and potential investors.

carlton griffiths :

Andy-Lai : What's the situation?

QM137over1 Andy-Lai : Washing out inventory for shipment.